More promisingly, two independent studies have shown that the efficacy of the KRASG12C inhibitor ARS-1620 was increased when combined with mTOR and an IGF1R inhibitor [15] and PI3K inhibitor [14] in lung cancer cells and in vivo models. This evidence concerns the gene MTOR and lung carcinoma.